# FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older
Canonical URL: https://biopharmsignal.com/news/ASND/fda-approves-once-weekly-yuviwelr-navepegritide-for-children-with-achondroplasia-aged-2-years-and-older
Ticker: ASND
Company: Ascendis Pharma
Source: Ascendis Pharma
Published: 2026-02-27 22:57 EST
Original Source URL: https://investors.ascendispharma.com
## Summary

The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing interval Commercial availability expected during early part of Q2 2026 Rare Pediatric Disease Priority Review Voucher granted in connection with approval Ascendis to host

## Article Body
The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing interval Commercial availability expected during early part of Q2 2026 Rare Pediatric Disease Priority Review Voucher granted in connection with approval Ascendis to host
## Recent Company News
- 2026-06-30 12:30 EST — [Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial](https://biopharmsignal.com/news/ASND/children-with-achondroplasia-treated-with-transcon-cnp-showed-continued-improvem-93d02f62) — Source: Ascendis Pharma
- 2026-06-26 20:01 EST — [Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®](https://biopharmsignal.com/news/ASND/ascendis-joins-multiple-russell-u-s-indexes-including-the-russell-3000-russell-1-d1ad8aa7) — Source: Ascendis Pharma
- 2026-06-25 20:01 EST — [Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026](https://biopharmsignal.com/news/ASND/ascendis-to-showcase-advances-in-treatment-of-achondroplasia-at-iccbh-2026-cf687b9b) — Source: Ascendis Pharma
- 2026-06-13 20:00 EST — [Phase 3 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH Through Week 182 in Adults with Hypoparathyroidism](https://biopharmsignal.com/news/ASND/phase-3-data-show-transcon-pth-replicated-systemic-actions-of-endogenous-pth-thr-c45e7bfc) — Source: Ascendis Pharma
- 2026-06-11 20:01 EST — [5-Year Phase 2 Data Show TransCon® PTH Replicated Systemic Actions of Endogenous PTH in Adults with Hypoparathyroidism](https://biopharmsignal.com/news/ASND/5-year-phase-2-data-show-transcon-pth-replicated-systemic-actions-of-endogenous--57728427) — Source: Ascendis Pharma
## Related News
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)
- 2026-07-29 12:25 EST — ICCM — [IceCure: SIO Petitions NCCN to Include Cryoablation in Breast Cancer Treatment Guidelines, Citing IceCure's FDA Clearance  of ProSense®](https://biopharmsignal.com/news/ICCM/icecure-sio-petitions-nccn-to-include-cryoablation-in-breast-cancer-treatment-gu-bec46cd3)